AbbVie Inc (ABBV):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】AbbVie Inc (ABBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9980)・商品コード:DATA904C9980
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:315
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virology and metabolic therapy areas. The company also offers medicines for neurological disorders and other serious health conditions. AbbVie discovers and develops novel medicines based on protein-based and targeted drug delivery technologies. The company its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.

AbbVie Inc (ABBV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 11
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17
AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
AbbVie Inc, Pharmaceuticals & Healthcare, Deal Details 27
Asset Purchase 27
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 27
AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 28
AbbVie Acquires Rights to Ribasphere from Kadmon 29
Venture Financing 30
Morphic Therapeutic Raises USD80 Million in Series B Financing 30
ApoGen Biotech Raises Additional USD4 Million in Series A Financing 32
Quentis Therapeutics Raises USD48 Million in Series A Financing 34
Jnana Therapeutics Raises USD50 Million in Series A Financing 36
Palleon Pharma Raises USD47.6 Million in Series A Financing 37
Disarm Therapeutics Raises USD30 Million in Series A Financing 38
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 39
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 41
CARMA Therapeutics Raises Fund through Venture Financing 43
ApoGen Biotech Raises USD7 Million in Series A Financing 44
Artios Pharma Raises USD33.2 Million in Series A Financing 46
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 48
Lodo Therapeutics Raises USD17 Million in Series A Financing 50
Alector Raises USD29.5 Million in Series D Financing 52
Petra Pharma Raises USD48 Million in Series A Financing 54
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 56
Stemcentrx Raises USD500 Million in Financing Round 58
Stemcentrx Raises USD250 Million in Financing Round 59
Stem CentRx Raises more than USD100 Million in Financing Round 60
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 61
Virobay Raises USD8 Million in Extended Series B Financing 63
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 65
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 67
Avaxia Biologics Raises US$11.4 Million In Series B Financing 68
Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 70
Partnerships 71
AbbVie and Morphic Therapeutic to Enter into Agreement 71
Tolero Pharma Enters into Research Agreement with AbbVie 72
IRICoR, University of Montreal Enter into Research Agreement with AbbVie 73
Oncternal Therapeutics Enters into Agreement with Pharmacyclics 75
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 76
AbbVie Enters into Agreement with Alector 78
AbbVie and Harpoon Therapeutics Enter into Research Partnership 79
AbbVie and Turnstone Biologics Enter into Research Agreement 80
AbbVie and Bristol-Myers Squibb Enter into Agreement 81
AbbVie and Principia Biopharma Enter into Agreement 82
Argen-X Enters Into Agreement with AbbVie 83
Zebra Biologics Enters into Agreement with AbbVie 84
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 85
AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 86
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 87
AbbVie Enters into Agreement with BioArctic 88
X-Chem Enters into Co-Development Agreement with AbbVie 89
AbbVie and Bristol-Myers Squibb Enter into Agreement 90
EA Pharma Enters into Co-Promotion Agreement with AbbVie 91
AbbVie Enters into Research Agreement with University of Chicago 92
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 93
Philogen Enters into R&D Agreement with AbbVie 94
Synlogic Enters into R&D Agreement with AbbVie 95
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 96
AbbVie Deutschland Enters into Partnership Agreement with Eisai 97
Enterome Enters into Co-Development Agreement with AbbVie 98
Calico Expands Co-Development Agreement with AbbVie 99
Seattle Genetics Expands Co-Development Agreement With AbbVie 100
Myriad Genetics Expands Research Agreement with AbbVie 101
AbbVie Expands its Agreement with Galapagos 102
AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 104
Inventiva Extends Agreement with AbbVie 105
Licensing Agreements 106
AbbVie Enters into Licensing Agreement with Momenta Pharma 106
AbbVie Exercises Option for Licensing Agreement with Argenx 107
Mylan Enters into Licensing Agreement with AbbVie 108
AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 109
E-Scape Enters into Licensing Agreement with AbbVie 110
Samsung Bioepis Enters into Licensing Agreement with AbbVie 111
AbbVie Exercises Option for Licensing Agreement with X-Chem 112
AbbVie Exercises Option for Licensing Agreement with Philogen 113
AbbVie Enters into Licensing Agreement with Pure MHC 114
AbbVie Enters into Licensing Agreement with Dong-A ST 115
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 116
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 118
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 120
AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer’s Disease Therapy 121
AbbVie Enters into Licensing Agreement with Apogenix 122
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 123
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 124
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 125
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 126
F-star Bio Enters into Licensing agreement with AbbVie 127
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 128
Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 129
Equity Offering 130
Exicure Raises USD20 Million in Private Placement 130
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 131
Pharmacyclics Completes Public Offering Of Shares For US$207 Million 132
AbbVie Spin Out from Abbott Laboratories 133
AbbVie Completes IPO 134
Debt Offering 135
AbbVie Raises USD1.25 Billion in Public Offering of 3.375% Notes Due 2021 135
AbbVie Raises USD1.25 Billion in Public Offering of 3.75% Notes Due 2023 137
AbbVie Raises USD1.75 Billion in Public Offering of 4.25% Notes Due 2028 139
AbbVie Raises USD1.75 Billion in Public Offering of 4.875% Notes Due 2048 141
AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 143
AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 144
AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 145
AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 146
AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 148
AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 150
AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 152
AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 154
AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 156
AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 158
AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 160
AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 162
AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 164
AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 166
AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 168
AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 169
AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 170
AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 171
Acquisition 172
AbbVie Acquires Stemcentrx 172
AbbVie Acquires Pharmacyclics 173
AbbVie Acquires ImmuVen from Serra Ventures 175
AbbVie Inc – Key Competitors 176
AbbVie Inc – Key Employees 177
AbbVie Inc – Locations And Subsidiaries 178
Head Office 178
Other Locations & Subsidiaries 178
Recent Developments 187
Strategy And Business Planning 187
Jan 16, 2018: AbbVie Expands Oncology Capability at the Company’s Site in Ballytivnan, Sligo 187
Financial Announcements 188
Sep 30, 2018: Abbvie reports third-quarter 2018 financial results 188
Jul 27, 2018: AbbVie Reports Second-Quarter 2018 Financial Results 190
Apr 26, 2018: AbbVie Reports First-Quarter 2018 Financial Results 193
Jan 26, 2018: AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results 195
Oct 27, 2017: AbbVie Reports Third-Quarter 2017 Financial Results 197
Jul 28, 2017: AbbVie Reports Second-Quarter 2017 Financial Results 199
Apr 27, 2017: AbbVie Reports First-Quarter 2017 Financial Results 201
Jan 27, 2017: AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results 203
Corporate Communications 205
Oct 19, 2018: AbbVie announces senior management change 205
Sep 21, 2018: AbbVie announces $5 Million donation to family reach to support children battling cancer and their families 206
Aug 20, 2018: AbbVie announces 100 million donation to Ronald McDonald House Charities to support hospitalized children and their families 207
May 22, 2018: AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico 208
Jul 31, 2017: AbbVie Announces Delisting from Euronext Paris 210
Legal and Regulatory 211
Mar 28, 2018: AbbVie pays $5m to man who claims testosterone drug caused heart attack 211
Government and Public Interest 212
Oct 24, 2018: AbbVie to assume full development and commercial control of Cystic Fibrosis research program 212
Oct 15, 2018: Rival companies to tap $20bn global market with biosimilars for Humira 213
Dec 05, 2017: Bioethics International Releases the “Good Pharma Scorecard” in BMJ Open, Ranking the Top 20 Largest Pharmaceutical Companies on Clinical Trial Transparency 214
Mar 28, 2017: AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program 215
Product News 216
12/14/2017: LSTMs A·WOL Consortium Celebrates 10-year Milestone 216
11/21/2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition 217
11/01/2017: Data To Be Presented On Venclexta At ASH 2017 Annual Meeting 218
10/30/2017: Janssen Announces IMBRUVICA (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review 219
10/25/2017: Nail psoriasis data now part of HUMIRA label 221
10/24/2017: New hope of a treatment for aggressive T-PLL leukaemia 222
10/24/2017: AbbVie to Present New Data on HUMIRA at the 2017 ACR/ARHP Annual Meeting 223
09/25/2018: AbbVie receives approval from health canada for the combination of VENCLEXTA with Rituximab as a treatment for patients with chronic lymphocytic leukemia 225
08/30/2017: China Food and Drug Administration approves IMBRUVICA (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs 226
08/29/2017: More Canadians have access to HUMIRA (adalimumab) for the treatment of Ulcerative Colitis 227
08/02/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) – A Serious, Potentially Life-Threatening Condition – After Failure of One or More Lines of Systemic Therapy 228
07/28/2017: FDA grants breakthrough therapy designation for Venclexta in acute myeloid leukaemia 230
07/21/2017: AbbVie Receives CHMP Positive Opinion for HUMIRA (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis 231
06/28/2018: argenx receives second preclinical milestone payment under its development agreement with AbbVie 233
06/21/2018: AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA 234
06/13/2017: AbbVie Presents Real-World Data Evaluating the Relationship between Participation in a Patient Support Program and Outcomes in Patients with Moderate to Severe Rheumatoid Arthritis 235
06/11/2018: AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA 237
06/08/2018: AbbVie Announces U.S. FDA Approval of VENCLEXTA (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy 238
06/05/2017: New Data Presented at ASCO 2017 Finds IMBRUVICA (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients 241
05/22/2017: New cancer drug can prevent reactions to common airborne allergens 243
05/16/2018: AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting 244
04/13/2018: Two Clinical Trials Demonstrate Effectiveness Of Venetoclax 245
04/13/2017: argenx receives first preclinical milestone payment in AbbVie collaboration 246
04/11/2017: Scottish Medicines Consortium recommends Imbruvica (ibrutinib) for restricted use in patients with Chronic Lymphocytic Leukaemia in Scotland 247
04/05/2018: Chemo Free Cancer Treatment Thanks To Victorian Research 248
03/30/2017: U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie’s HUMIRA (adalimumab) Prescribing Information 249
03/23/2018: AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-a Monoclonal Antibody HUMIRA in the Treatment of Patients who have had an Inadequate Response to Conventional Therapy for Pustular Psoriasis 250
03/06/2018: AbbVie Receives Positive Recommendation from the Pan-Canadian Oncology Drug Review for VENCLEXTA – an Oral Therapy for the Treatment of Patients with Chronic Lymphocytic Leukemia 251
02/21/2018: Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA (Adalimumab) to manage their disease 252
01/26/2017: National Institute for Health and Care Excellence (NICE) approves Imbruvica (ibrutinib) for routine NHS use in patients with chronic lymphocytic leukaemia 253
01/19/2017: U.S. FDA Approves IMBRUVICA (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) – a Rare Type of Non-Hodgkin’s Lymphoma 254
Product Approvals 256
Jul 12, 2018: AbbVie submits venetoclax sNDA for acute myeloid leukaemia 256
Jan 15, 2018: AbbVie’s Humira Rejects For Use Within NHS Scotland 257
Nov 13, 2017: Janssen-Cilag’s Imbruvica Rejects For Use Within NHS Scotland 258
Sep 28, 2017: NICE U-turn on Imbruvica(ibrutinib) means patients with Waldenstrom’s macroglobulinaemia can now access the only licensed novel agent available for this rare blood cancer 259
Aug 07, 2017: Scotland first in the UK to make VENCLYXTO (venetoclax) routinely available for patients with most common form of leukaemia 260
Jun 12, 2017: AbbVie’s Humira accepted for use in NHS Scotland 262
Jun 12, 2017: Janssen-Cilag’s Imbruvica Rejects For Use Within NHS Scotland 263
Apr 25, 2017: AbbVie Files Application for Humira in Japan for Additional Indication of Pustular Psoriasis 264
Apr 04, 2017: U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy 265
Jan 10, 2017: Australian Approval For Drug That ‘Melts’ Leukaemia 266
Clinical Trials 267
Oct 24, 2018: Galapagos announces topline interim results of FALCON trial Part 1 with in CF 267
Oct 24, 2018: Galapagos announces topline interim results of FALCON trial Part 1 in cystic fibrosis 268
Sep 11, 2018: Minimal residual disease negativity data, a measure of undetectable disease, added to VENCLEXTA (venetoclax tablets) label 269
Jun 28, 2018: Topline results of PELICAN trial and update on triple combo development plans 271
Jun 15, 2018: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress 272
May 31, 2018: AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress 274
Apr 24, 2018: Galapagos reports initiation of FALCON clinical trial in cystic fibrosis 276
Feb 12, 2018: AbbVie to Present Data on HUMIRA at 2018 American Academy of Dermatology Annual Meeting 277
Jan 03, 2018: Galapagos: Update on Progress in GLPG2222 Cystic Fibrosis Program 278
Jan 02, 2018: Galapagos Announces First dosing in Phase 1 study with second triple combination 279
Jan 02, 2018: Galapagos Announces Start of Phase 1 study with GLPG2851, $10 million milestone payment 280
Jan 02, 2018: Galapagos Expects first dosing of CF patient with investigational triple combination therapy 281
Dec 12, 2017: AbbVie Announces Phase 3 Study of VENCLEXTA/ VENCLYXTO (venetoclax) in Combination with Rituxan (rituximab) Meets its Primary Endpoint 282
Nov 21, 2017: AbbVie to Present Data on Ibrutinib at the 2017 American Society of Hematology Annual Meeting & Exposition 284
Nov 21, 2017: Galapagos initiates Phase 1 study with novel CF corrector GLPG3221 286
Nov 21, 2017: Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition 287
Nov 19, 2017: ALBATROSS with GLPG2222 shows positive clinical results in CF patients 289
Nov 01, 2017: Janssen to Present Abstracts on IMBRUVICA (ibrutinib) at ASH 2017 290
Oct 05, 2017: NICE recommends access to AbbVie’s VENCLYXTO (venetoclax) to treat most common form of adult leukaemia in England via Cancer Drugs Fund 292
Sep 18, 2017: Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan 294
Jun 24, 2017: European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids 295
Jun 23, 2017: Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers 296
Jun 19, 2017: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma 298
Jun 12, 2017: AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress 300
Jun 05, 2017: Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukaemia Patients Treated with Imbruvica (ibrutinib), Including Those with High-Risk Disease, with Up to Four Years of Follow-Up 302
Jun 05, 2017: Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease 304
May 17, 2017: Janssen to Present Data on Ibrutinib at the American Society of Clinical Oncology 306
May 14, 2017: IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 307
Apr 19, 2017: AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer 309
Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie 310
Mar 22, 2017: Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 311
Feb 24, 2017: Evaluating A Novel Chemo-free Combination Therapy for Lymphocytic Leukemia 312
Feb 23, 2017: Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 313
Feb 01, 2017: Galapagos doses first patient with novel CF corrector GLPG2222 314
Appendix 315
Methodology 315
About GlobalData 315
Contact Us 315
Disclaimer 315

List of Tables
AbbVie Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
AbbVie Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
AbbVie Inc, Deals By Therapy Area, 2012 to YTD 2018 15
AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17
AbbVie Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
AbbVie Acquires Rights of BI-655066 and BI-655064 from Boehringer Ingelheim 27
AbbVie Acquires Active Pharmaceutical Ingredient Manufacturing Facility 28
AbbVie Acquires Rights to Ribasphere from Kadmon 29
Morphic Therapeutic Raises USD80 Million in Series B Financing 30
ApoGen Biotech Raises Additional USD4 Million in Series A Financing 32
Quentis Therapeutics Raises USD48 Million in Series A Financing 34
Jnana Therapeutics Raises USD50 Million in Series A Financing 36
Palleon Pharma Raises USD47.6 Million in Series A Financing 37
Disarm Therapeutics Raises USD30 Million in Series A Financing 38
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 39
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 41
CARMA Therapeutics Raises Fund through Venture Financing 43
ApoGen Biotech Raises USD7 Million in Series A Financing 44
Artios Pharma Raises USD33.2 Million in Series A Financing 46
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 48
Lodo Therapeutics Raises USD17 Million in Series A Financing 50
Alector Raises USD29.5 Million in Series D Financing 52
Petra Pharma Raises USD48 Million in Series A Financing 54
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 56
Stemcentrx Raises USD500 Million in Financing Round 58
Stemcentrx Raises USD250 Million in Financing Round 59
Stem CentRx Raises more than USD100 Million in Financing Round 60
AM-Pharma Raised USD15.8 Million in Series E Venture Financing 61
Virobay Raises USD8 Million in Extended Series B Financing 63
Kala Pharma Raises Us$22.5 Million In Series B Venture Financing 65
AuraSense Therapeutics Raises Funds Through Extended Series B Financing 67
Avaxia Biologics Raises US$11.4 Million In Series B Financing 68
Alvine Pharmaceuticals Secures USD70 Million in Venture Funding from AbbVie Biotech Ventures 70
AbbVie and Morphic Therapeutic to Enter into Agreement 71
Tolero Pharma Enters into Research Agreement with AbbVie 72
IRICoR, University of Montreal Enter into Research Agreement with AbbVie 73
Oncternal Therapeutics Enters into Agreement with Pharmacyclics 75
Voyager Therapeutics Enters into Agreement with AbbVie Biotechnology 76
AbbVie Enters into Agreement with Alector 78
AbbVie and Harpoon Therapeutics Enter into Research Partnership 79
AbbVie and Turnstone Biologics Enter into Research Agreement 80
AbbVie and Bristol-Myers Squibb Enter into Agreement 81
AbbVie and Principia Biopharma Enter into Agreement 82
Argen-X Enters Into Agreement with AbbVie 83
Zebra Biologics Enters into Agreement with AbbVie 84
AbbVie Enters into Agreement with Genomics Medicine Ireland and WuXi NextCODE Genomics 85
AbbVie Enters into Research Agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University 86
AbbVie Enters into Research Agreement with Johns Hopkins University School of Medicine 87
AbbVie Enters into Agreement with BioArctic 88
X-Chem Enters into Co-Development Agreement with AbbVie 89
AbbVie and Bristol-Myers Squibb Enter into Agreement 90
EA Pharma Enters into Co-Promotion Agreement with AbbVie 91
AbbVie Enters into Research Agreement with University of Chicago 92
Myriad Genetics Expands Research Agreement with AbbVie for Veliparib 93
Philogen Enters into R&D Agreement with AbbVie 94
Synlogic Enters into R&D Agreement with AbbVie 95
AbbVie Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 96
AbbVie Deutschland Enters into Partnership Agreement with Eisai 97
Enterome Enters into Co-Development Agreement with AbbVie 98
Calico Expands Co-Development Agreement with AbbVie 99
Seattle Genetics Expands Co-Development Agreement With AbbVie 100
Myriad Genetics Expands Research Agreement with AbbVie 101
AbbVie Expands its Agreement with Galapagos 102
AbbVie Enters Into Co-Development Agreement With Alvine Pharma For ALV003 104
Inventiva Extends Agreement with AbbVie 105
AbbVie Enters into Licensing Agreement with Momenta Pharma 106
AbbVie Exercises Option for Licensing Agreement with Argenx 107
Mylan Enters into Licensing Agreement with AbbVie 108
AbbVie to Enter into Licensing Agreement with California Institute for Biomedical Research 109
E-Scape Enters into Licensing Agreement with AbbVie 110
Samsung Bioepis Enters into Licensing Agreement with AbbVie 111
AbbVie Exercises Option for Licensing Agreement with X-Chem 112
AbbVie Exercises Option for Licensing Agreement with Philogen 113
AbbVie Enters into Licensing Agreement with Pure MHC 114
AbbVie Enters into Licensing Agreement with Dong-A ST 115
AbbVie Enters into Licensing Agreement with CytomX Therapeutics 116
AbbVie Enters into Licensing Agreement with CytomX Therapeutics for CD71 118
Halozyme Therapeutics Enters into Licensing Agreement with AbbVie 120
AbbVie Enters into License Agreement with C2N Diagnostics for Alzheimer’s Disease Therapy 121
AbbVie Enters into Licensing Agreement with Apogenix 122
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 123
AbbVie Enters into Licensing Agreement with Kadmon for Ribasphere 124
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 125
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 126
F-star Bio Enters into Licensing agreement with AbbVie 127
Medicines Patent Pool Enters into Licensing Agreement with AbbVie 128
Receptos Enters Into Licensing Agreement With AbbVie For RPC4046 129
Exicure Raises USD20 Million in Private Placement 130
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 131
Pharmacyclics Completes Public Offering Of Shares For US$207 Million 132
AbbVie Spin Out from Abbott Laboratories 133
AbbVie Completes IPO 134
AbbVie Raises USD1.25 Billion in Public Offering of 3.375% Notes Due 2021 135
AbbVie Raises USD1.25 Billion in Public Offering of 3.75% Notes Due 2023 137
AbbVie Raises USD1.75 Billion in Public Offering of 4.25% Notes Due 2028 139
AbbVie Raises USD1.75 Billion in Public Offering of 4.875% Notes Due 2048 141
AbbVie Raises USD795.6 Million in Public Offering of 2.13% Notes Due 2028 143
AbbVie Raises USD1.53 Billion in Public Offering of 1.38% Notes Due 2024 144
AbbVie Raises USD1.48 Billion in Public Offering of 0.38% Notes Due 2019 145
AbbVie to Raise USD1.8 Billion in Public Offering of 2.3% Notes Due 2021 146
AbbVie to Raise USD2 Billion in Public Offering of 4.45% Notes Due 2046 148
AbbVie to Raise USD1 Billion in Public Offering of 2.85% Notes Due 2023 150
AbbVie to Raise USD2 Billion in Public Offering of 3.2% Notes Due 2026 152
AbbVie to Raise USD1 Billion in Public Offering of 4.3% Notes Due 2036 154
AbbVie Raises USD3 Billion in Public Offering of 1.8% Notes Due 2018 156
AbbVie Raises USD3.75 Billion in Public Offering of 3.6% Notes Due 2025 158
AbbVie Raises USD2.5 Billion in Public Offering of 4.5% Notes Due 2035 160
AbbVie Raises USD3.75 Billion in Public Offering of 2.5% Notes Due 2020 162
AbbVie Raises USD1 Billion in Public Offering of 3.2% Notes Due 2022 164
AbbVie Raises USD2.7 Billion in Public Offering of 4.7% Notes Due 2045 166
AbbVie Raises USD1 Billion in Public Offering of 2% Notes Due 2018 168
AbbVie Raises USD2.6 Billion in Public Offering of 4.4% Notes Due 2042 169
AbbVie Raises USD3.1 Billion in Public Offering of 2.9% Notes Due 2022 170
AbbVie Raises USD4 Billion in Public Offering of 1.75% Notes Due 2017 171
AbbVie Acquires Stemcentrx 172
AbbVie Acquires Pharmacyclics 173
AbbVie Acquires ImmuVen from Serra Ventures 175
AbbVie Inc, Key Competitors 176
AbbVie Inc, Key Employees 177
AbbVie Inc, Subsidiaries 178

List of Figures
AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
AbbVie Inc, Medical Devices Deals, 2012 to YTD 2018 17

★調査レポート[AbbVie Inc (ABBV):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9980)販売に関する免責事項を必ずご確認ください。
★調査レポート[AbbVie Inc (ABBV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆